Page last updated: 2024-08-26

nicotine and liraglutide

nicotine has been researched along with liraglutide in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
López, M1
Ashare, RL; Audrain-McGovern, J; Hayes, MR; Herman, RJ; Schmidt, HD1
Clemmensen, C; Dmytriyeva, O; Ejdrup, AL; Falk, S; Gether, U; Hecksher-Sørensen, J; Jørgensen, SH; Kohlmeier, KA; Krauth, N; Ludwig, MQ; Lundø, K; Nielsen, DAG; Pers, TH; Petersen, J; Romero-Leguizamón, CR; Roostalu, U; Skovbjerg, G; Svendsen, C1

Reviews

1 review(s) available for nicotine and liraglutide

ArticleYear
Hypothalamic AMPK and energy balance.
    European journal of clinical investigation, 2018, Volume: 48, Issue:9

    Topics: Adipose Tissue, Brown; Adipose Tissue, White; AMP-Activated Protein Kinases; Animals; Anti-Obesity Agents; Antipsychotic Agents; Energy Metabolism; Feeding Behavior; Glucose; Homeostasis; Humans; Hypoglycemic Agents; Hypothalamus; Liraglutide; Liver; Metformin; Muscles; Nicotine; Nicotinic Agonists; Signal Transduction; Thermogenesis; Weight Gain

2018

Other Studies

2 other study(ies) available for nicotine and liraglutide

ArticleYear
Liraglutide attenuates nicotine self-administration as well as nicotine seeking and hyperphagia during withdrawal in male and female rats.
    Psychopharmacology, 2023, Volume: 240, Issue:6

    Topics: Animals; Extinction, Psychological; Female; Hyperphagia; Liraglutide; Male; Nicotine; Obesity; Rats; Self Administration; Tobacco Use Disorder

2023
GLP-1 and nicotine combination therapy engages hypothalamic and mesolimbic pathways to reverse obesity.
    Cell reports, 2023, 05-30, Volume: 42, Issue:5

    Topics: Animals; Dopamine; Glucagon-Like Peptide 1; Liraglutide; Mice; Nicotine; Obesity

2023